Antares Pharma Inc (NASDAQ:ATRS) Opens Trade Around the $2.15 Mark

[[tagnumber 0]][[tagnumber 1]]Forty minutes into today‘s market session, Antares Pharma Inc (NASDAQ:ATRS) is currently traded at $2.15 per share, which is only three cents below the price at which some of the company‘s directors acquired a total of 1.75 million shares after exercising their stock options on May 28, 2015. The latter got revealed earlier today as a slew of SEC Form 4‘s flooded ATRS‘ filing dossier.[[tagnumber 2]] [[tagnumber 0]]Now that the directors of the emerging pharmaceutical company have acquired their shares at near–market value, the incentive to maximize stock value in the coming months seems to be there.[[tagnumber 2]] [[tagnumber 0]]Antares Pharma is an emerging business engaged in a mixture of development programs, licensing agreements and clinical trials for its self–administered pharmaceutical drug products. One of them, the Vibex auto injector for OTREXUP (methotrexate) injection has already been cleared by the FDA and the company is generating revenue streams from it. Another one, the Vibex Quickshot Testosterone, or QST, is doing well during phase 3 of its clinical trial, yet the company will need to bring in another 70 testosterone–deficient patients for a six–month period to align with the FDA‘s recommendations before moving forward with the actual commercialization of the product. The latter will most probably not commence until next year at the earliest.[[tagnumber 2]] [[tagnumber 0]][[tagnumber 8]]According to Antares‘s latest 10–Q, the company‘s cash reserves dwindled by more than $10 million for the three–month period ended Mar. 31, 2015. The net loss of $6.8 million, however, marked a slight improvement on an annual basis. A huge surge in revenue is evident, as well – $4.6 million vs $1.8 million in Q1 2014. Due to OTREXUP‘s relatively short market history so far, making firm projections about how well it will perform in the forthcoming quarters is nothing short of a forward looking statement.[[tagnumber 2]] [[tagnumber 0]]Prior to April 16, Antares shares had been riding an upward wave on the charts. This trend has since turned upside down and ATRS stock has, as a result, lost roughly 30 per cent of its market value. If the 8–K from that same day is anything to go by, the way the patent infringement lawsuit was settled has so far failed to raise the stakes. Investors are advised to keep track of how Antares‘s QST product candidate will perform en route to getting a full FDA clearance.[[tagnumber 2]]